Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b
Phil McEwan(Health Economics and Outcomes Research (United Kingdom)), Hiromitsu Kumada(Toranomon Hospital), Kristine Broglio(Berry & Associates (United States)), Melanie Quintana(Berry & Associates (United States)), Isao Kamae(The University of Tokyo), Samantha Webster(Health Economics and Outcomes Research (United Kingdom)), Sachie Inoue, Thomas Ward(Edward Hines, Jr. VA Hospital), Masahiro Kobayashi(Toranomon Hospital), Anupama Kalsekar(Bristol-Myers Squibb (United States)), Yong Yuan(Kunming Medical University), Ann Tang(Bristol-Myers Squibb (Japan)), Scott Berry(Queen's University)
Cited by 16
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818